10:27 AM EST - BioVaxys Technology Corp : Announces today they have entered into a Research Agreement to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform in combination with Sona's Targeted Hyperthermia Therapy™, a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary biocompatible Gold Nanorod technology which elicits a strong immune response. BioVaxys Technology Corp
shares C.BIOV are trading unchanged at $0.03.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=6462649513763739
